PsyKey, Inc. Announces Renowned Biochemist Dr. Michael J. McCarthy as Member of Scientific & Medical Advisory Board
PsyKey, Inc. Announces Renowned Biochemist Dr. Michael J. McCarthy as Member of Scientific & Medical Advisory Board
CARSON CITY, NV, Nov. 16, 2022 (GLOBE NEWSWIRE) -- CECORS, INC. (OTC PINK: CEOS) ("CeCors" or the "Company"), through its wholly owned subsidiary PsyKey Inc., an innovative wellness company, is pleased to announce the appointment of Dr. Michael J. McCarthy, Ph.D. to its scientific and medical advisory board.
內華達州卡森市，2022年11月16日(環球通訊社)CECORS，Inc.(場外粉色：首席執行官)(“CeCors”或“公司”)，通過其全資擁有的子公司--一家創新的保健公司，宣佈任命邁克爾·J·麥卡錫博士為其科學和醫療顧問委員會的成員。
Dr. McCarthy joins PsyKey with over 35 years of experience serving as a consultant to the biopharmaceutical industry and formulating high-impact pharmaceuticals and nutraceuticals. A biochemist and widely published author, Dr. McCarthy offers PsyKey his extensive expertise in securing biomedical patents and intellectual properties.
麥卡錫博士擁有35年以上擔任生物製藥行業顧問和制定高影響力藥物和保健食品的經驗。作為一名生物化學家和出版廣泛的作家，麥卡錫博士在保護生物醫學專利和知識產權方面為GeorKey提供了豐富的專業知識。
"Dr. McCarthy is a scientist who truly understands the important link between the chemical compounds in food and optimum health," said John Gustin, PsyKey head of global business development. "With his extensive knowledge of the biotechnical patent landscape, we are confident Dr. McCarthy will make significant contributions to our ongoing product development efforts."
“麥卡錫博士是一位科學家，他真正瞭解食品中的化合物與最佳健康之間的重要聯繫，”心理鑰匙公司全球商業發展負責人約翰·古斯汀説。憑藉他在生物技術專利領域的廣博知識，我們相信麥卡錫博士將為我們正在進行的產品開發努力做出重大貢獻。“
"I am very excited to join PsyKey," said McCarthy. "There is a great deal of synergy between the interests of the research team at PsyKey and my long-term biomedical studies. For many years we've understood the neurological benefits of certain medicinal and psychedelic mushrooms, but we're just now unlocking the real potential of these remarkable fungi. I am confident my experience enhancing the potency and bio-availability of micro-nutrients will help further distinguish PsyKey, as an industry-leading innovative wellness company."
麥卡錫説：“我很高興能加入《心理鑰匙》。他説：“我們的研究團隊的興趣和我的長期生物醫學研究之間有很大的協同作用。多年來，我們已經瞭解了某些藥用和迷幻蘑菇的神經益處，但我們現在才釋放出這些非凡真菌的真正潛力。我相信，我提高微量營養素的效力和生物可利用性的經驗將有助於進一步區分作為一家行業領先的創新健康公司。”
Prior to joining PsyKey, Dr. McCarthy spent eight years at Scripps Research, ranked the most influential institution in the world for its impact on innovation as their biotechnology patent agent, while working on numerous ground-breaking technologies which have had major market influence. Among his many contributions to the biomedical field, Dr. McCarthy developed the "Agent/Enhancer" technology to increase the potency of biochemical factors used in therapeutics for anxiety, cancer, and sleep enhancement.
在加入GeorKey之前，麥卡錫博士在斯克裏普斯研究公司工作了8年，作為他們的生物技術專利代理人，斯克裏普斯研究公司將其對創新的影響評為世界上最有影響力的機構，同時從事許多具有重大市場影響力的突破性技術。在他對生物醫學領域的眾多貢獻中，麥卡錫博士開發了“製劑/增強劑”技術，以提高焦慮、癌症和睡眠改善療法中使用的生化因子的效力。
With degrees in Biology and Physics from Benedictine College, Dr. McCarthy attended The Johns Hopkins University School of Medicine, where he participated in the Biochemistry, Cellular and Molecular Biology program. McCarthy went on to earn his Ph.D. from the Department of Biochemistry at Vanderbilt University. His Postdoctoral Studies in Endocrinology at Vanderbilt included developing viral and transgenic systems leading to the reversal of atherosclerosis in laboratory animals.
麥卡錫博士擁有本尼迪克廷學院的生物學和物理學學位，曾就讀於約翰霍普金斯大學醫學院，並在那裏參加了生物化學、細胞和分子生物學項目。麥卡錫後來在範德比爾特大學生物化學系獲得博士學位。他在範德比爾特大學內分泌學的博士後研究包括開發病毒和轉基因系統，從而逆轉實驗室動物的動脈粥樣硬化。
About PsyKey, Inc.
關於心理鑰匙公司
PsyKey, Inc. is an innovative wellness company that specializes in the development and commercialization of mycology-based entheogenic, adaptogenic, and nootropic ingredients and formulations. From functional to medicinal PsyKey, Inc. believes in the magic of mushrooms. As part of its optimal wellness strategy, PsyKey understands the importance of access to support services and healthcare professionals. Management is continuously engaged in the development of tools that will aid in removing barriers and providing inclusivity.
辛基公司是一家創新的保健公司，專門從事以真菌學為基礎的致病、致適應和促性成分和配方的開發和商業化。從功能到藥用，心理鑰匙公司相信蘑菇的魔力。作為其最佳健康戰略的一部分，CogKey瞭解獲得支持服務和醫療保健專業人員的重要性。管理層不斷致力於開發有助於消除障礙和提供包容性的工具。
For further information:
有關更多信息，請訪問：
(OTC Pink: CEOS)
(場外粉色：首席執行官)
E-mail: info@psykeyworld.com
Follow us on Twitter:
電子郵件：info.ping.com.cn
在推特上關注我們：
Forward-Looking Statements:
Safe Harbour Statement - In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company's future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency, and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company's business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company's website. The Company disclaims any responsibility to update any forward- looking statements.
前瞻性陳述：
安全港聲明-除歷史信息外，本新聞稿可能包含符合1933年《證券法》和經1995年《私人證券訴訟改革法》修訂的1934年《證券交易法》所指的前瞻性陳述。本新聞稿中包含的前瞻性陳述包括公司及其管理團隊成員對公司未來業務運營的意圖、信念或期望，以及這些陳述所基於的假設。提醒潛在投資者，任何此類前瞻性陳述都不是對未來業績的保證，涉及風險和不確定因素，實際結果可能與此類前瞻性陳述中預期的大不相同。可能導致這些差異的因素包括但不限於：未能完成談判中的預期銷售、收入增長乏力、客户中斷、未能實現業績、效率和盈利能力的改善，以及訴訟或訴訟成本增加、公司業務部門的運營或業績或其普通股的市場價格方面的不利發展。其他可能導致實際結果與本新聞稿中預期的大不相同的因素也可以在公司網站上找到。公司不承擔任何更新任何前瞻性陳述的責任。
譯文內容由第三人軟體翻譯。